clock menu more-arrow no yes

HeartFlow is the newest unicorn after a new $150 million financing round

The medical company is now valued at $1.4 billion.

A doctor in a white coat talks to an older patient Joe Raedle / Getty

The medical technology company HeartFlow is now valued at over $1 billion, the latest company to hit the category threshold for the most highly valued startups.

HeartFlow is expected to collect $150 million in a new fundraising round, according to a new regulatory filing in Delaware uncovered by PitchBook. At a price of about $25.33 per share, HeartFlow will have a valuation of $1.4 billion.

The company did not immediately respond to a request for comment. It last raised money at a $760 million valuation in May 2016, according to PitchBook.

HeartFlow, founded in 2010, sells a product to doctors to detect coronary artery disease.

Investors have included U.S. Venture Partners, GE Ventures and the venture fund of insurer Blue Cross Blue Shield. The new backers of this funding round are not immediately known.


This article originally appeared on Recode.net.

Sign up for the newsletter Sign up for The Weeds

Get our essential policy newsletter delivered Fridays.